Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

Abdel-Rahmène Azzouzi(Université d'Angers), S. Vincendeau(Inserm), Éric Barret(Délégation Paris 5), Antony Cicco, F. Kleinclauss(Centre Hospitalier Universitaire de Besançon), Henk G. van der Poel(The Netherlands Cancer Institute), Christian G. Stief(LMU Klinikum), Jens Rassweiler(SLK-Kliniken Heilbronn), Georg Salomon(Universität Hamburg), Eduardo Solsona(Fundación Instituto Valenciano de Oncología), Antonio Alcaraz(Hospital Clínic de Barcelona), Teuvo T. L. Tammela(Tampere University Hospital), Derek J. Rosario(Royal Hallamshire Hospital), F. Gómez-Veiga(Universidade da Coruña), Göran Ahlgren(Skåne University Hospital), Fawzi Benzaghou(Paris Biotech Santé), B. Gaillac(Paris Biotech Santé), Billy Amzal, F.M.J. Debruyne(Andros Mannenkliniek), Gaëlle Fromont(Université de Tours), Christian Gratzke(LMU Klinikum), Mark Emberton(The London College)
The Lancet Oncology
December 19, 2016
Cited by 330

Abstract


Related Papers

No related papers found

Powered by citation graph analysis